Provision of investigational drug after clinical research - Review of literature, national and international guidelines

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDAINESI, Sonia Mansoldo
dc.contributor.authorGOLDBAUM, Moises
dc.date.accessioned2017-11-27T16:34:06Z
dc.date.available2017-11-27T16:34:06Z
dc.date.issued2011
dc.description.abstractProvision of investigational drug after clinical research - Review of literature, national and international guidelines The post-trial access to investigational drugs has been the object of discussion since the late 1980s at least, initially linked to trials carried out in acquired immunodeficiency syndrome and, particularly, in developing countries, where the concern with patient vulnerability is more important. National and international guidelines do mention the subject; however, the complexity of the issue is not easily addressed and usually requires additional and specific discussions. The decision on providing the investigational drug after the trial shall rest on at least two dimensions: efficacy and safety assessments, as the new drug is still on the experimental phase. Each clinical trial shall have its own assessment, taking into account the disease being studied, as well as the study population and their specific needs. Therefore, the nature of post-trial obligations cannot be considered the same in all situations and contexts; nevertheless, it should be assured that the relationship developed between investigators and patients during the study must be always terminated with respect and responsibility.
dc.description.indexMEDLINE
dc.identifier.citationREVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.57, n.6, p.710-716, 2011
dc.identifier.issn0104-4230
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23370
dc.language.isopor
dc.publisherASSOC MEDICA BRASILEIRA
dc.relation.ispartofRevista da Associacao Medica Brasileira
dc.rightsopenAccess
dc.rights.holderCopyright ASSOC MEDICA BRASILEIRA
dc.subjectContinuity of patient care
dc.subjectdrugs, investigational
dc.subjectclinical research
dc.subjectbioethics
dc.subjectethics committees, research
dc.subjectvulnerability
dc.subject.otherdeveloping-countries
dc.subject.otherposttrial access
dc.subject.otherresearch participants
dc.subject.othertrials
dc.subject.otherinterventions
dc.subject.otherhiv/aids
dc.subject.otherethics
dc.subject.otherviews
dc.subject.othercare
dc.subject.wosMedicine, General & Internal
dc.titleProvision of investigational drug after clinical research - Review of literature, national and international guidelines
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcSONIA MANSOLDO DAINESI
hcfmusp.contributor.author-fmusphcMOISES GOLDBAUM
hcfmusp.description.beginpage710
hcfmusp.description.endpage716
hcfmusp.description.issue6
hcfmusp.description.volume57
hcfmusp.origemWOS
hcfmusp.origem.pubmed22249554
hcfmusp.origem.wosWOS:000298265100020
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referencePace C, 2006, AIDS RES HUM RETROV, V22, P837, DOI 10.1089/aid.2006.22.837
hcfmusp.relation.referenceFalit BP, 2008, JAMA-J AM MED ASSOC, V300, P2793, DOI 10.1001/jama.2008.828
hcfmusp.relation.referenceZong ZY, 2008, J MED ETHICS, V34, P188, DOI 10.1136/jme.2006.018754
hcfmusp.relation.referenceHamilton EP, 2010, J CLIN ONCOL, V28, P5067, DOI 10.1200/JCO.2010.28.6567
hcfmusp.relation.referenceBarsdorf N, 2010, DEV WORLD BIOETH, V10, P78, DOI 10.1111/j.1471-8847.2009.00265.x
hcfmusp.relation.referenceCabral MML, 2006, REV SAUDE PUBL, V40, P521, DOI [10.1590/S0034-89102006000300022, 10.1590/s0034-89102006000300022]
hcfmusp.relation.referenceCiaranello AL, 2009, HIV CLIN TRIALS, V10, P13, DOI [10.1310/hct1001-013, 10.1310/hct1001-13]
hcfmusp.relation.reference*CNS, REL REUN AMPL CONEP
hcfmusp.relation.referenceCohen E. R. M., 2008, DEV WORLD BIOETH, V9, P74
hcfmusp.relation.referenceCouncil for International Organizations of Medical Sciences (CIOMS), 2002, INT ETH GUID BIOM RE
hcfmusp.relation.referenceDAINESI SM, 2011, THESIS U SAO PAULO
hcfmusp.relation.referenceDainesi SM, 2009, REV ASSOC MED BRAS, V55, P237, DOI 10.1590/S0104-42302009000300006
hcfmusp.relation.referenceDEUCHER KLA, 2009, THESIS U SAO PAULO
hcfmusp.relation.referenceGoldim JR, 2008, REV PANAM SALUD PUBL, V23, P198, DOI 10.1590/S1020-49892008000300007
hcfmusp.relation.referenceGRADY C, 2006, ETHICS J AM MED ASS, V8, P235
hcfmusp.relation.reference*IND LIAIS FOR, 20022003 IND LIAIS F
hcfmusp.relation.referenceKAAS N, 2001, ETHICAL POLICY ISSUE, V2
hcfmusp.relation.referenceLacativa PGS, 2008, CIENCIA SAUDE COLETI, V13, P611
hcfmusp.relation.referenceNational Bioethics Advisory Commission, 2001, ETH POL ISS RES INV
hcfmusp.relation.reference*NIH, NIH GUID ADDR PROV A
hcfmusp.relation.reference*NUFF COUNC BIOETH, 2002, WHAT HAPP ONC RES IS
hcfmusp.relation.referenceOrganizacao das Nacoes Unidas para a Educacao a Ciencia e a Cultura (Unesco), 2005, DECL UN BIOET DIR HU
hcfmusp.relation.referenceSchlemper-Junior BR, 2007, REV BIOETICA, V15, P248
hcfmusp.relation.referenceSchroeder D, 2008, RECIIS REV ELETR S1, V2, pS66
hcfmusp.relation.referenceShaffer DN, 2006, J MED ETHICS, V32, P55, DOI 10.1136/jme.2004.011106
hcfmusp.relation.referenceShah S, 2009, AM J PUBLIC HEALTH, V99, P1556, DOI 10.2105/AJPH.2008.157982
hcfmusp.relation.referenceSofaer N, 2009, J MED ETHICS, V35, P183, DOI 10.1136/jme.2008.024711
hcfmusp.relation.referenceWorld Medical Association (WMA), DECL HELS
relation.isAuthorOfPublicationd28ae220-e924-459d-90e6-1cdcddb38877
relation.isAuthorOfPublicationb6efe731-bda2-41d9-82ac-a32d5fd65d62
relation.isAuthorOfPublication.latestForDiscoveryd28ae220-e924-459d-90e6-1cdcddb38877
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
art_DAINESI_Provision_of_investigational_drug_after_clinical_research_Review_2011.PDF
Tamanho:
2.17 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)